+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2014-10-28Number of Pages: 81

Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market (Drug Eluting Beads, Polyvinyl Alcohol (PVA) Particles, Microspheres, Gelatin-based Embolization Devices, Selective Internal Radiation Therapy (SIRT), Onyx, TRUFILL n Butyl Cyano Acrylate (nBCA) Liquid Embolic System and Nanoparticles) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

This study on novel drug delivery systems (NDDS) in cancer therapy comprises study of technologies such as embolization devices, liquid embolics and nanoparticles that offer unique approaches in cancer remedy. Several embolic agents are used by interventional radiologists for the selective occlusion of arteries supplying blood to tumors. The selection of an embolic agent depends on various factors including size of the vessel to be embolized, desired clinical outcome, duration of the vessel to be occluded, and also the intrinsic properties and behavior of the embolic agent. Nanoparticles as drug delivery systems have emerged as a promising technology to treat patients suffering from various types of cancer. Owing to their small size, nanoparticles exhibit unique physicochemical and biological properties, and thus help in overcoming several limitations such as poor bio-distribution, non-specific drug delivery, low therapeutic indices, and lack of water solubility which are mostly associated with conventional drug delivery.

This report studies the global market for NDDS in cancer therapy encompassing three major technologies: embolization particles, liquid embolics and nanoparticles. Each of these technologies has been analyzed in detail from product analysis, market trends, recent developments, future outlook and opportunities, to the competitive landscape. The report provides market size in terms of USD million for each technology for the period 2012 to 2020, considering the macro and micro environmental factors. In addition, the compounded annual growth rate (CAGR) of the overall NDDS in cancer therapy market and the segments has also been provided in the report for the forecast period 2014 to 2020, considering 2012 and 2013 as the base years. This report includes an elaborate executive summary, which covers a market snapshot representing key findings from the study.

Geographically, the NDDS in cancer therapy market has been classified into four regions namely, North America, Europe, Asia Pacific and Rest of the World (RoW). The market size and forecast for each of these regions along with CAGR for the forecast period from 2014 to 2020 have also been provided in the report. A detailed qualitative analysis of the major factors determining market dynamics such as drivers, restraints and opportunities, along with the market attractiveness analysis are discussed in the market overview section of the NDDS in cancer therapy market report. A section describing the U.S. and EU regulatory pathways has also been included. The study on NDDS in cancer therapy suggests a list of recommendations for new companies willing to enter the market and for existing companies to accentuate shares, which is likely to help in the decision-making process. ANSOFF matrix analysis has also been provided for the key players in this market. The competitive landscape section has been provided for each technology separately and presents the market revenue share of key players in terms of percentage for the year 2013. The market share analysis of key players involved the study of company product portfolio, sales revenue, and geographical presence along with market developments such as new product launch, brand recall, regulatory approvals, etc.

The study is a robust combination of primary and secondary research. Primary research formed the bulk of our research efforts with information collected from telephonic interviews and interaction via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases for patents, clinical trials, demographics, disease incidence/prevalence, etc. The key players operating in the NDDS in cancer therapy market are Advanced Medical Isotope Corporation, Bind Therapeutics, Boston Scientific Corporation, BTG plc, CeloNova BioSciences, Inc., Cook Medical, Inc., Cospheric LLC, Covidien, plc, Eckert & Ziegler BEBIG, EmboMedics, Inc., Kobo Products, Inc., Merit Medical Systems, Inc., Mo-Sci Corporation, Nanobiotix, Polysciences, Inc., Sirtex Medical, Inc. and Terumo Medical Corporation.

The global NDDS in cancer therapy market is segmented as follows:

NDDS in Cancer Therapy Market, by Technology
  • Embolization Particles
    • Current Technologies
      • Drug Eluting Beads
      • Others (PVA particles, microspheres, gelatin-based)
    • Emerging Technologies
      • Selective Internal Radiation Therapy (SIRT)
        • TheraSphere
        • SIR-Spheres
      • Holmium-based Microspheres
    • Liquid Embolics
      • Onyx (LES and HD-500)
      • TRUFILL nBCA LES
    • Nanoparticles
NDDS in Cancer Therapy Market, by Geography
  • North America
    • Embolization Particles
    • Liquid Embolics
    • Nanoparticles
  • Europe
    • Embolization Particles
    • Liquid Embolics
    • Nanoparticles
  • Asia Pacific
    • Embolization Particles
    • Liquid Embolics
    • Nanoparticles
  • Rest of the World (RoW)
    • Embolization Particles
    • Liquid Embolics
    • Nanoparticles


Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
     1.3.1 Sources
             1.3.1.1 Secondary Research
             1.3.1.2 Primary Research
     1.3.2 Assumptions and Limitations
     1.3.3 List of Abbreviations

Chapter 2 Executive Summary
2.1 Market Snapshot: Global NDDS in Cancer Therapy Market (2013 & 2020)
2.2 Global NDDS in Cancer Therapy Market, by Technology, 2013 (USD Million)
2.3 Comparative Analysis: Global NDDS in Cancer Therapy Market Revenue, by Geography, 2013 & 2020 (Value %)

Chapter 3 Market Overview
3.1 Introduction
3.2 Global Prevalence and Incidence Data
     3.2.1 Global Historical Prevalence (Number of Cases), by Major Cancer Type (2008 - 2012)
     3.2.2 Global Prevalence Forecast (Number of Cases), by Major Cancer Type (2013 - 2020)
     3.2.3 Global Historical Incidence (Number of Cases), by Major Cancer Type (2008 - 2012)
     3.2.4 Global Incidence Forecast (Number of Cases), by Major Cancer Type (2013 - 2020)
3.3 Current Major Indications for NDDS in Cancer Therapy
     3.3.1 Liver Cancer
     3.3.2 Pancreatic Cancer
     3.3.3 Bile Duct Cancer
     3.3.4 Colorectal Cancer
     3.3.5 Arteriovenous Malformations
     3.3.6 Hypervascular Malignant Tumors
     3.3.7 Aneurysms
3.4 Drivers
     3.4.1 Growing incidence of various types of cancer
     3.4.2 Clinical benefits of embolic agents and nanoparticles over other therapy and drug delivery systems
     3.4.3 Technological advances leading to the development of new and innovative therapy
     3.4.4 Expanding therapeutic indications of NDDS
3.5 Restraints
     3.5.1 High treatment cost associated with NDDS
     3.5.2 Strict regulatory pathway and high cost associated with new product development
3.6 Opportunities
     3.6.1 Investing in the development of nano-enabled drug delivery systems
3.7 Regulatory Pathway to Commercialization
     3.7.1 U.S. Food and Drug Administration (FDA)
             3.7.1.1 Major Steps: U.S. FDA Regulatory Approval Pathway
     3.7.2 EU (CE Marking)
             3.7.2.1 Major Steps: CE Marking Regulatory Approval Pathway
3.8 Event Impact Analysis
3.9 Market Attractiveness Analysis: Global NDDS in Cancer Therapy Market, by Geography

Chapter 4 Global Embolization Particles Market Revenue, by Type
4.1 Overview
     4.1.1 Global Embolization Particles Market Revenue, by Type, 2012 - 2020 (USD Million)
4.2 Current Technologies
     4.2.1 Drug Eluting Beads
             4.2.1.1 Global Drug Eluting Beads Market Revenue, 2012 - 2020 (USD Million)
     4.2.2 Other Current Technologies
             4.2.2.1 Global Other Current Technologies Market Revenue, 2012 - 2020 (USD Million)
             4.2.2.2 Polyvinyl Alcohol (PVA) Particles
             4.2.2.3 Microspheres
             4.2.2.4 Gelatin-based Embolization Devices
4.3 Emerging Technologies
     4.3.1 Selective Internal Radiation Therapy (SIRT) / Radioembolization
             4.3.1.1 Global SIRT/ Radioembolization Market Revenue, 2012 - 2020 (USD Million)
             4.3.1.2 SIR-Spheres Microspheres
                       4.3.1.2.1 Global SIR-Spheres Market Revenue, 2012 – 2020 (USD Million)
             4.3.1.3 TheraSphere
                       4.3.1.3.1 Global TheraSphere Market Revenue, 2012 – 2020 (USD Million)
     4.3.2 Holmium-based Microspheres
4.4 Recent Events
4.5 Competitive Analysis
     4.5.1 Market Share Analysis: Embolization Particles, by Key Players, 2013 (Value %)

Chapter 5 Global Liquid Embolics Market Revenue, by Brand
5.1 Overview
     5.1.1 Global Liquid Embolics Market Revenue, by Brand, 2012 - 2020 (USD Million)
     5.1.2 Onyx
             5.1.2.1 Global Onyx Devices Market Revenue, 2012 - 2020 (USD Million)
     5.1.3 TRUFILL n Butyl Cyano Acrylate (nBCA) Liquid Embolic System
             5.1.3.1 Global TRUFILL nBCA Liquid Embolic Systems Market Revenue, 2012 – 2020 (USD Million)
5.2 Recent Developments
5.3 Competitive Analysis
     5.3.1 Market Share Analysis: Liquid Embolics, by Key Players, 2013 (Value %)

Chapter 6 Global Nanoparticles Market Revenue
6.1 Overview
     6.1.1 Global Nano-enabled Drug Delivery Systems in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
     6.1.2 Approved Nano-enabled Drug Delivery Systems for Cancer Treatment
     6.1.3 Nano-enabled Drug Delivery Systems in Cancer Treatment Under Clinical Investigation
     6.1.4 Emerging Technologies and Treatments
             6.1.4.1 Nanocarriers
6.2 Competitive Analysis
     6.2.1 Market Share Analysis: Nanoparticles, by Key Players, 2013 (Value %)

Chapter 7 Global NDDS in Cancer Therapy Market, by Geography
7.1 Overview
     7.1.1 Global NDDS in Cancer Therapy Market Revenue, by Geography, 2012 - 2020 (USD Million)
7.2 North America
     7.2.1 North America NDDS in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
     7.2.2 North America NDDS in Cancer Therapy Market Revenue, by Technology, 2012 - 2020 (USD Million)
7.3 Europe
     7.3.1 Europe NDDS in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
     7.3.2 Europe NDDS in Cancer Therapy Market Revenue, by Technology, 2012 - 2020 (USD Million)
7.4 Asia Pacific
     7.4.1 Asia Pacific NDDS in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
     7.4.2 Asia Pacific NDDS in Cancer Therapy Market Revenue, by Technology, 2012 - 2020 (USD Million)
7.5 Rest of the World
     7.5.1 Rest of the World NDDS in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
     7.5.2 Rest of the World NDDS in Cancer Therapy Market Revenue, by Technology, 2012 - 2020 (USD Million)

Chapter 8 Recommendations
8.1 Strategies for Success
8.2 ANSOFF Matrix

List of Figures

FIG. 1 Market Segmentation: NDDS in Cancer Therapy
FIG. 2 Global NDDS in Cancer Therapy Market, by Technology, 2013 (USD Million)
FIG. 3 Comparative Analysis: Global NDDS in Cancer Therapy Market Revenue, by Geography, 2013 & 2020 (Value %)
FIG. 4 Global Historical Prevalence (Number of Cases), by Major Cancer Type (2008 - 2012)
FIG. 5 Global Prevalence Forecast (Number of Cases), by Major Cancer Type (2013 - 2020)
FIG. 6 Global Historical Incidence (Number of Cases), by Major Cancer Type (2008 - 2012)
FIG. 7 Global Incidence Forecast (Number of Cases), by Major Cancer Type (2013 - 2020)
FIG. 8 Major Steps: U.S. FDA Regulatory Approval Pathway
FIG. 9 Major Steps: CE Marking Regulatory Approval Pathway
FIG. 10 Market Attractiveness Analysis: Global NDDS in Cancer Therapy Market, by Geography
FIG. 11 Global Drug Eluting Beads Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 Global Other Current Technologies Market Revenue, 2012 - 2020 (USD Million)
FIG. 13 Global SIRT/ Radioembolization Market Revenue, 2012 - 2020 (USD Million)
FIG. 14 Global SIR-Spheres Market Revenue, 2012 – 2020 (USD Million)
FIG. 15 Global TheraSphere Market Revenue, 2012 – 2020 (USD Million)
FIG. 16 Market Share Analysis: Embolization Particles, by Key Players, 2013 (Value %)
FIG. 17 Global Onyx Devices Market Revenue, 2012 - 2020 (USD Million)
FIG. 18 Global TRUFILL nBCA Liquid Embolic Systems Market Revenue, 2012 – 2020 (USD Million)
FIG. 19 Market Share Analysis: Liquid Embolics, by Key Players, 2013 (Value %)
FIG. 20 Global Nano-enabled Drug Delivery Systems in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
FIG. 21 Market Share Analysis: Nanoparticles, by Key Players, 2013 (Value %)
FIG. 22 North America NDDS in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
FIG. 23 Europe NDDS in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
FIG. 24 Asia Pacific NDDS in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
FIG. 25 Rest of the World NDDS in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
FIG. 26 ANSOFF Matrix: NDDS in Cancer Therapy Market

List of Tables

TABLE 1 List of Abbreviations
TABLE 2 Market Snapshot: Global NDDS in Cancer Therapy Market (2013 & 2020)
TABLE 3 Event Impact Analysis: Global NDDS in Cancer Therapy Market
TABLE 4 Global Embolization Particles Market Revenue, by Type, 2012 - 2020 (USD Million)
TABLE 5 Global Liquid Embolics Market Revenue (Forecast), by Brand, 2012 - 2020 (USD Million)
TABLE 6 Approved Nano-enabled Drug Delivery Systems for Cancer Treatment
TABLE 7 Nano-enabled Drug Delivery Systems in Cancer Treatment Under Clinical Investigation
TABLE 8 Global NDDS in Cancer Therapy Market Revenue, by Geography, 2012 - 2020 (USD Million)
TABLE 9 North America NDDS in Cancer Therapy Market Revenue, by Technology, 2012 – 2020 (USD Million)
TABLE 10 Europe NDDS in Cancer Therapy Market Revenue, by Technology, 2012 - 2020 (USD Million)
TABLE 11 Asia Pacific NDDS in Cancer Therapy Market Revenue, by Technology, 2012 - 2020 (USD Million)
TABLE 12 Rest of the World NDDS in Cancer Therapy Market Revenue, by Technology, 2012 - 2020 (USD Million)

The world is witnessing a continuous rise in the incidence of various types of cancer. Clinical benefits of embolic agents and nanoparticles over other therapy and drug delivery systems; technological advances leading to the development of new and innovative therapy; and expanding therapeutic indications of existing NDDS are some of the major factors expected to drive growth of the global NDDS in cancer therapy market during the forecast period from 2014 to 2020. On the other hand, factors such as high treatment cost associated with NDDS, strict regulatory pathways and cost associated with new product development may restrict market growth to some extent. One of the major opportunities in this market is nano-enabled drug delivery systems as this segment has been anticipated to grow at the highest CAGR of 24.7% during the forecast period.

The global market for NDDS in cancer therapy was valued at USD 3,655.3 million in 2013 and is expected to reach USD 15,984.2 million in 2020, growing at a CAGR of 23.7% during the forecast period from 2014 to 2020. Embolization particles, liquid embolics and nanoparticles as drug delivery systems altogether comprise the global market for NDDS in cancer therapy. PVA particles, microspheres, drug eluting beads (DEB) and selective internal radiation therapy (SIRT) are the major products under the embolization particles market segment, while Onyx LES and TRUFILL nBCA LES are the two major liquid embolic system brands. The liquid embolics market segment is expected to grow at a CAGR of 4.9% during the forecast period from 2014 to 2020. Nanoparticles in novel drug delivery systems have emerged as a promising technology to treat patients suffering from various types of cancer. The market for nanoparticles segment was valued at USD 3,307.7 million in 2013 with the largest revenue share in the overall NDDS in cancer therapy market. Over the past two decades, many nanoparticles such as Doxil (doxorubicin), Megace ES (megestrol acetate), Abraxane (paclitaxel), Myocet (doxorubicin), DepoCyt (liposomal cytarabine), and DaunoXome (daunorubicin citrate) have been approved as drug delivery systems for cancer therapy. 

Geographically, North America was the largest regional market for NDDS in cancer therapy in 2013, with a market share of 46.6%. Growing at a CAGR of 24.9% during the forecast period 2014 to 2020, its market share is expected to reach 49.7% in 2020. Europe captured the second largest share after North America and accounted for 29.2% of the global market revenue in 2013. In the Asia Pacific region, Japan, China, India, Australia and New Zealand are the potential markets that offer enormous opportunities for NDDS in cancer therapy market to grow substantially in the region. Major factors that will be responsible for market growth in these markets include emerging economies, growing market penetration by major players in these regions and improvement in reimbursement scenario. The Asia Pacific market is expected to grow at a CAGR of 22.6% during the forecast period.

The key players operating in the NDDS in cancer therapy market are Advanced Medical Isotope Corporation, Bind Therapeutics, Boston Scientific Corporation, BTG plc, CeloNova BioSciences, Inc., Cook Medical, Inc., Cospheric LLC, Covidien, plc, Eckert & Ziegler BEBIG, EmboMedics, Inc., Kobo Products, Inc., Merit Medical Systems, Inc., Mo-Sci Corporation, Nanobiotix, Polysciences, Inc., Sirtex Medical, Inc. and Terumo Medical Corporation.

global-ndds-cancer-therapy-market


A complete brochure for this research is available for download.

Interact with our pool of experienced analysts for any report related queries